Photo: Getty Images
A new study, led by experts from the University of Nottingham, has shown that people with rare autoimmune rheumatic diseases are at a greater risk of dying at a younger age during the Covid-19 pandemic.
The findings of the study, published in the British Society for Rheumatology’s journal, Rheumatology, was the work of a team of doctors and researchers from RECORDER (Registration of Complex Rare Diseases Exemplars in Rheumatology), which is a joint project between the University of Nottingham and the National Disease Registration Service at Public Health England.
Experts looked at the electronic health records of 170,000 people in England with rare autoimmune rheumatic diseases. During March and April 202 (the first two months of the Covid-19 pandemic), the team found that 1,815 (1.1%) of people with these diseases died.
The results also showed that:
Paul Howard, Chief Executive of Lupus UK, said: “This study is an important step in helping us to understand the impact of the Covid-19 pandemic on people with rare autoimmune rheumatic conditions in the UK. The findings demonstrate that, as a group, people with conditions such as lupus have been disproportionately impacted and therefore the provision of additional support is necessary.
“We hope that the next steps of this research will lead to a clearer understanding about whether Covid-19 or other factors caused the increased mortality, and also whether other health and quality of life measures have been disproportionately affected in these patient groups.” Paul Howard, Chief Executive of LUPUS UK.”
Dr. Peter Lanyon, Consultant Rheumatologist at Nottingham University Hospitals NHS Trust, said: “Our study illustrates the unique ability of collaboration with the National Disease Registration Service to generate findings that can improve health in rare diseases. Further work to understand them in greater depth and more support for people with rare autoimmune rheumatic diseases is now needed."
Dr. Sanjeev Patel, President of the British Society for Rheumatology, said: “These results are incredibly important to the rheumatology community. These conditions might be rare, but when we look at them together it’s a significant number of people.
“This is a large study which shows for the first time that a subgroup of patients in our care are at an increased risk of dying during the pandemic and at a much younger age. We don’t yet know the reasons why, but this study brings into sharp focus the need to be more vigilant with these patients and it should help inform future shielding advice.”